Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

4.49USD
20 Apr 2018
Change (% chg)

$-0.02 (-0.44%)
Prev Close
$4.51
Open
$4.48
Day's High
$4.58
Day's Low
$4.38
Volume
214,042
Avg. Vol
269,930
52-wk High
$20.42
52-wk Low
$3.76

Select another date:

Fri, Apr 6 2018

BRIEF-Newlink Genetics Reviews Clinical Programs

* IN LIGHT OF INCYTE'S ANNOUNCEMENT REGARDING ECHO-301 TRIAL, CO UNDERTAKING REVIEW OF CLINICAL PROGRAMS Source text for Eikon: Further company coverage:

BRIEF-NewLink Genetics, Cantor Fitzgerald Enter Controlled Equity Offering Sales Agreement

* NEWLINK GENETICS SAYS ON MARCH 12, CO ENTERED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING

BRIEF-NewLink Genetics Qtrly Loss Per Share $0.37

* NEWLINK GENETICS REPORTS FOURTH QUARTER, YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES UPDATE FOR INDOXIMOD PROGRAMS

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

Select another date: